Article

Neutralization potential of Covishield vaccinated individuals sera against B.1.617.1

2021-05-12

Abstract excerpt

Covishield comprises the larger proportion in the vaccination program in India. Hence, it is of utmost importance to understand neutralizing capability of vaccine against the B.1.617.1 variant which is considered to responsible for surge of the cases in India. The neutralizing-antibody (NAb) titer against B.1.167.1 and prototype B.1 variant (D614G) was determined of the vaccine sera (4 weeks after second dose) of...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 1c128a5d-fcd1-5048-b9fe-fddf9678a22e
DOI: 10.1101/2021.05.12.443645

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Neutralization potential of Covishield vaccinated individuals sera against B.1.617.1DOI 10.1101/2021.05.12.443645Read

Neutralization of Delta variant with sera of Covishield vaccinees and COVID-19 recovered vaccinated individualsSemantic proximity Read

Covid-19 Vaccine Authorized in India-A Mini ReviewSemantic proximity Read

SARS-CoV-2 Delta derivatives impact on neutralization of Covishield recipient seraSemantic proximity Read

SARS-CoV-2 B.1.617 emergence and sensitivity to vaccine-elicited antibodiesSemantic proximity Read

COVID-19 Vaccine Authorized in India-A Mini ReviewSemantic proximity Read

Effectiveness of COVID-19 vaccines against the B.1.617.2 variantSemantic proximity Read

Comparable neutralization of SARS-CoV-2 Delta AY.1 and Delta in individuals sera vaccinated with BBV152Semantic proximity Read

SARS-CoV-2 B.1.617.2 Delta variant replication, sensitivity to neutralising antibodies and vaccine breakthroughSemantic proximity Read

Genomic analysis of SARS-CoV-2 breakthrough infections from Varanasi, IndiaSemantic proximity Read

Reduced sensitivity of infectious SARS-CoV-2 variant B.1.617.2 to monoclonal antibodies and sera from convalescent and vaccinated individualsSemantic proximity Read

Immunogenic superiority and safety of Biological E CORBEVAX vaccine compared to COVISHIELD (ChAdOx1 nCoV-19) vaccine studied in a phase III, single blind, multicenter, randomized clinical trialSemantic proximity Read

Reduced neutralisation of the Delta (B.1.617.2) SARS-CoV-2 variant of concern following vaccinationSemantic proximity Read